Ballerup, 29 January 2025 – Today, LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr will join the Global Leadership Team and serve as CEO and President, LEO Pharma Inc. United States. Robert succeeds Brian Hilberdink, who will be leaving LEO Pharma to pursue an external opportunity in a large pharmaceutical company.

Robert joined LEO Pharma in 2023 as Vice President of Market Access, Patient Services, Sales, and Health Economics and Outcomes Research (HEOR) and a member of the North America Leadership Team. Prior to LEO Pharma, he previously held numerous senior leadership positions at Novartis, Johnson and Johnson, and Repligen. Robert also served as President of Bausch Healthcare Companies Inc.  

“I am thrilled to step into the role of EVP of Region North America and CEO & President of LEO Pharma Inc. US,” said Robert Spurr “As LEO Pharma undergoes significant transformation with a clear strategy for the future, I am eager to leverage my experience to drive our continued success. With a strong growth trajectory and a dedicated team, I am confident we can deliver great results.”

Robert Spurr will officially step into the EVP role on January 29, 2025. Brian Hilberdink’s last day at LEO Pharma will be on February 11, 2025.

“During my tenure at LEO Pharma, I have witnessed the incredible drive and passion across Region North America. I’m proud to have had the opportunity to lead and help propel the Region into a significant growth trajectory,” said Brian Hilberdink, former EVP of Region North America and CEO & President of LEO Pharma Inc. US. “It has not been an easy decision to leave LEO Pharma, and I have every confidence in the future success of the organization.” 

“I would like to thank Brian for his key contribution in accelerating LEO Pharma’s growth trajectory in North America and for building a strong team,” said LEO Pharma CEO, Christophe Bourdon. “Robert’s track record and leadership qualities make him ideally suited to his new role. Over the last 18 months I have been truly impressed by his key contributions to the US affiliate. I would like to congratulate him on his appointment and welcome him as a member of LEO Pharma’s Global Leadership Team. His contributions will be instrumental in further strengthening our growth trajectory in North America.”